IndustryCompany release

BioCryst raises 2026 revenue guidance as ORLADEYO pellets win FDA clearance for ages 12+

🇺🇸 Biocryst Pharmaceuticals Inc (BCRX) · Wed 04 Nov 2026

The company reported third-quarter net revenue of $180.3M and lifted its full-year total revenue outlook, while the FDA approved an oral pellet formulation of ORLADEYO for hereditary angioedema.

BioCryst Pharmaceuticals reported third-quarter 2026 results on 4 November, with total net revenue of $180.3M. ORLADEYO contributed $174.8M of that figure, and the company posted an operating profit of $53.3M.

In October, the US Food and Drug Administration approved an oral pellet formulation of ORLADEYO for patients with hereditary angioedema (HAE) aged 12 and older. The source material available does not give further details on the pellet product, such as dosing or launch timing.

BioCryst raised its 2026 total revenue guidance to a range of $715M to $730M. Guidance for ORLADEYO revenue was left unchanged at $625M to $645M, and the company also lowered its outlook for non-GAAP operating expenses.

What it means for your team

  • Market-access teams tracking HAE should note the new pellet formulation for patients aged 12 and older, which may affect how the product is positioned within the prophylaxis landscape.
  • Regulatory teams can treat the October FDA approval as a precedent for age-appropriate oral formulations of established rare-disease therapies.
  • The unchanged ORLADEYO guidance alongside a higher total revenue outlook indicates the company expects growth from sources beyond ORLADEYO alone, although the source gives no breakdown.

Company's press release (SEC filing): Biocryst Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Biocryst Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →